Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 222,031,099 papers from all fields of science
Search
Sign In
Create Free Account
AZD3514
Known as:
Androgen Receptor Downregulator AZD3514
, SARD AZD3514
An orally available selective androgen receptor (AR) downregulator (SARD), with potential antineoplastic activity. Upon oral administration, AZD3514…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
AR protein, human
Inhibition of Cell Proliferation
Translational Repression
Broader (1)
Pyridazines
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Voie de signalisation des androgènes, altérations génomiques et progression du cancer de la prostate
P. Barthélémy
2016
Corpus ID: 91161427
La voie de signalisation du recepteur des androgenes (RA) reste une cible therapeutique privilegiee dans les cancers de la…
Expand
2016
2016
Systems Pharmacology Modeling of Prostate‐Specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down‐Regulator
H. Mistry
,
M. Fabre
,
J. Young
,
G. Clack
,
P. Dickinson
CPT: Pharmacometrics & Systems Pharmacology
2016
Corpus ID: 13237833
First‐in‐human (FIH) studies with AZD3514, a selective androgen receptor (AR) down‐regulator, showed decreases of >30% in the…
Expand
2016
2016
The value of integrating pre-clinical data to predict nausea and vomiting risk in humans as illustrated by AZD3514, a novel androgen receptor modulator.
C. Grant
,
L. Ewart
,
+4 authors
P. Newham
Toxicology and Applied Pharmacology
2016
Corpus ID: 21926629
2016
2016
Clinical pharmacology profile of an oral selective androgen receptor down-regulator, AZD3514: Implications on the design of ongoing castrate-resistant prostate cancer clinical studies
A. Dymond
,
M. Fabre
,
+5 authors
G. Clack
2016
Corpus ID: 79292599
Purpose: To describe the pharmacokinetics (PK) and pharmacodynamics (PD) of AZD3514 and how the design of the first-time-in-human…
Expand
2016
2016
Abstract LB-107: Androgen receptor inhibitor enhances the antitumor effect of PARP inhibitor in breast cancer cells via modulation of DNA damage response
A. Min
,
S. Im
,
+10 authors
Y. Bang
2016
Corpus ID: 78324112
Introduction: Olaparib, a PARP inhibitor has produced promising antitumor efficacy in patients with BRCA mutation. However…
Expand
2014
2014
Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells
J. Cummings
,
R. Sloane
,
+6 authors
C. Dive
BMC Cancer
2014
Corpus ID: 255804381
AZD3514 inhibits and down regulates the androgen receptor (AR) and has undergone clinical trials in prostate cancer. To provide…
Expand
2013
2013
A first-in-human study of the oral selective androgen receptor down-regulating drug (SARD) AZD3514 in patients with castration-resistant prostate cancer (CRPC).
A. Omlin
,
Robert Jones
,
+14 authors
T. Elliott
2013
Corpus ID: 78484550
4511 Background: AZD3514 is a first in class, orally bio-available drug that inhibits androgen-dependent and –independent…
Expand
2012
2012
Abstract 3848: Preclinical profile of AZD3514: A small molecule-targeting androgen receptor function with a novel mechanism of action and the potential to treat castration-resistant prostate cancer
S. Loddick
,
R. Bradbury
,
+15 authors
N. Brooks
2012
Corpus ID: 72641875
The androgen receptor (AR), an important molecular target in the aetiology and progression of prostate cancer, has been found…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE